Sale disclosed
Neil Kumar
Chief Executive Officer
Common Stock
- Reported value
- $601.87K
- Reported price
- $69.0136 / share
Loading data…Scanning SEC filings…Checking Congress reports…Following the signal…
BridgeBio Pharma, Inc.
Last 30 daysNo qualifying insider buying. Sales: $690.85K by 1 insider.
Showing the first 6 of 20 trades on this page.
Chief Executive Officer
Common Stock
Chief Executive Officer
Common Stock
Chief Executive Officer
Common Stock
Chief Executive Officer
Common Stock
Chief Executive Officer
Common Stock
Chief Executive Officer
Common Stock
Chief Executive Officer
Common Stock
Chief Executive Officer
Common Stock
Chief Executive Officer
Common Stock
Chief Accounting Officer
Common Stock
Director
Common Stock
Director
Common Stock
Director
Common Stock
Director
Common Stock
Director
Common Stock
Director
Common Stock
Director
Common Stock
Director
Common Stock
Director
Common Stock
Chief Executive Officer
Common Stock
| Reporting insider | Security / transaction | Amount / price | Value | Traded / disclosed | Source |
|---|---|---|---|---|---|
| Chief Executive Officer | Common StockSale10b5-12 trades | 10,000avg $69.08 / share | $690.85K | Sep 17Filed Sep 21 · 4d later | 2 filings
|
| Chief Executive Officer | Common StockSale10b5-14 trades | 34,980avg $82.53 / share | $2.89M | Aug 18Filed Aug 20 · 2d later | 4 filings
|
| Chief Executive Officer | Common StockSale10b5-13 trades | 10,000avg $84.03 / share | $840.26K | Aug 19Filed Aug 20 · 1d later | 3 filings
|
| Chief Accounting Officer | Common StockSale10b5-1 | 2,000$80.06 / share | $160.12K | Jul 30Filed Aug 3 · 4d later | SEC filing |
| Director | Common StockSale10b5-1 | 17,167$84.00 / share | $1.44M | Jul 9Filed Jul 13 · 4d later | SEC filing |
| Director | Common StockSale10b5-12 trades | 148,589avg $88.54 / share | $13.16M | Jul 9Filed Jul 13 · 4d later | 2 filings
|
| Director | Common StockSale10b5-1 | 2,196$68.57 / share | $150.58K | Jun 23Filed Jun 24 · 1d later | SEC filing |
| Director | Common StockSale10b5-1 | 37,167$70.00 / share | $2.6M | Jun 24Filed Jun 24 · 0d later | SEC filing |
| Director | Common StockSale10b5-1 | 2,808$68.00 / share | $190.94K | Jun 22Filed Jun 24 · 2d later | SEC filing |
| Director | Common StockSale10b5-1 | 2,196$68.57 / share | $150.58K | Jun 23Filed Jun 24 · 1d later | SEC filing |
| Director | Common StockSale10b5-12 trades | 90,240avg $66.62 / share | $6.01M | Jun 15Filed Jun 17 · 2d later | 2 filings
|
| Chief Executive Officer | Common StockSale10b5-1 | 2,200$65.72 / share | $144.58K | Jun 4Filed Jun 8 · 4d later | SEC filing |
Showing the latest 20 of 65 trades. Show all 65 trades
BridgeBio Pharma, Inc. - Common Stock (BBIO) · Stock
The filing reports a purchase for the member.
Gilbert CisnerosReporting House memberBridgeBio Pharma, Inc. - Common Stock (BBIO) · Stock
The filing reports a purchase for the member.
Gilbert CisnerosReporting House memberBridgeBio Pharma, Inc. - Common Stock (BBIO) · Stock
The filing reports a purchase for the member.
Gilbert CisnerosReporting House memberBridgeBio Pharma, Inc. - Common Stock (BBIO) · Stock
The filing reports a purchase for the member.
Gilbert CisnerosReporting House memberBridgeBio Pharma, Inc. - Common Stock (BBIO) · Stock
The filing reports a purchase for the member.
Gilbert CisnerosReporting House memberBridgeBio Pharma, Inc. - Common Stock (BBIO) · Stock
The filing reports a purchase for the member.
Gilbert CisnerosReporting House memberNo eligible common-equity purchase is public by this cutoff within 180 transaction-date days. Other instruments, exercises and routine activity do not contribute purchase points.
This score describes qualifying insider purchases at issuer level. Read the methodology
Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.
Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.